{
  "pmcid": "3563805",
  "sha256": "b6fa099348c8456e3e1e30c964311ff0e70c35c096e1a301607e75d1ff960d6c",
  "timestamp_utc": "2025-11-09T23:49:06.144295+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.310150000000004,
    "reading_ease": 34.634825000000006,
    "word_count": 250
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Acridine Orange Therapy Versus Conventional Wide-Margin Resection in Soft Tissue Sarcoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either acridine orange therapy (n=51) or conventional wide-margin resection (n=119)."
      },
      "Participants": {
        "score": 1,
        "evidence": "This randomised controlled trial included 170 patients with high-grade soft tissue sarcoma treated between 1999 and 2009."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either acridine orange therapy (n=51) or conventional wide-margin resection (n=119)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates a less radical surgical approach using adjunctive acridine orange therapy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was overall survival at 10 years."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group allocation."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Participants were randomised to receive either acridine orange therapy (n=51) or conventional wide-margin resection (n=119)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The 10-year overall survival rates were 68% for the acridine orange group and 63% for the conventional group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported in either group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}